Immutep & MSD Published New Interim Data of Eftilagimod Alpha + Keytruda (pembrolizumab) in P-II (TACTI-002) Trial as 2L Treatment of NSCLC at ELCC 2022
Shots:
- The P-II (TACTI-002) trial evaluates Immutep’s eftilagimod alpha + MSD’s pembrolizumab in 36 patients with PD-L1 unselected PD-X refractory metastatic NSCLC
- As of the data cut-off date of Jan 21, 2022, 73.7% of evaluable patients (14/19) had tumour shrinkage or tumour growth deceleration, 73% were alive @6mos. in the difficult-to-treat patient population, ORR of 5.6% (2/36) with 2 patients reporting confirmed & durable partial responses for ~9 & 23mos. , DCR of 36.1% with PFS (26%) @6mos.
- Additionally, 6 patients still under therapy in the trial, m-OS has not yet been reached, was safe & well-tolerated. The therapy also showed encouraging early signs of antitumour activity
Ref: Pharmiweb | Image: Wikipedia
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
